The PD-1 receptor, a major immune checkpoint inhibitor whose signaling is the target of multiple blockbuster anticancer drugs, differs functionally between rodents and humans in previously unknown ...

The addition of sintilimab to neoadjuvant chemoradiotherapy achieved a 60% pathological complete response rate vs 47.3% with chemoradiotherapy alone in locally advanced ESCC.

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown ... and potentially a replacement for checkpoint inhibitor standard-of-care treatments for a range of ...

Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by targeting key immune pathways such as PD-1, PD-L1, CTLA-4, and LAG-3 to enhance the immune system's ability to combat ...

BeiGene’s trials suggest that this mechanism, combined with chemotherapy, offers survival benefits in PD-L1-expressing cancers. Tevimbra is part of a competitive PD-1 inhibitor market ...

Merck and its rivals make tens of billions of dollars a year from the mechanism and are ... regardless of PD-L1 expression. Junshi, Coherus' PD-1 inhibitor Loqtorzi scores in phase 3 liver cancer ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

More information: Ignacio Melero et al, Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours, Nature (2024). DOI: 10.1038/s41586-024-08305-z ...

The optimal therapeutic dosage is 0.5-1 mg administered ... to MAO-B inhibition, rasagiline has demonstrated neuroprotective properties in experimental laboratory models. The mechanisms whereby ...